Publications by authors named "Phyllis Flomenberg"

We describe a case of culture-negative right-sided endocarditis for which simultaneous transcatheter vegetectomy was performed with leadless pacemaker implantation and removal of a temporary externalized pacing system. The patient did not have a recurrence of endocarditis highlighting the safety and efficacy of same-procedure vegetation removal and pacemaker implantation. This report documents a novel approach for the treatment of cardiac implantable electronic device-associated endocarditis in poor surgical candidates who are pacemaker-dependent.

View Article and Find Full Text PDF

Cytotoxic T lymphocytes (CTLs) destroy virally infected cells and are critical for the elimination of viral infections such as those caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Delayed and dysfunctional adaptive immune responses to SARS-CoV-2 are associated with poor outcomes. Treatment with allogeneic SARS-CoV-2-specific CTLs may enhance cellular immunity in high-risk patients providing a safe, direct mechanism of treatment.

View Article and Find Full Text PDF

Since its identification as a unique species in 1982, has been implicated as a pathogenic organism in very few cases of human disease. Our report discusses a case of bacteremia with identified by Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) and RapID ONE analysis in a patient getting TPN through a peripherally-inserted CVC (PICC). The PICC was removed.

View Article and Find Full Text PDF

We report the first published case of acute pancreatitis secondary to disseminated nocardiosis in a hematopoietic stem cell transplant (HSCT) recipient on chronic immunosuppression for graft-versus-host disease (GVHD). Nocardiosis in the HSCT population is relatively rare, and has not yet been described in haploidentical HSCT recipients. Our patient is a 28-year-old male with a history of haploidentical HSCT and GVHD of the skin and lung who was admitted to the hospital with acute pancreatitis.

View Article and Find Full Text PDF

Haploidentical hematopoietic stem cell transplantation (HSCT) is an attractive alternative donor option based on the rapid availability of an acceptable donor for most patients and decreased cost compared with costs of other alternative donor strategies. The safety of haploidentical HSCT has increased in recent years, making it ethically feasible to offer to patients with earlier stage disease. We developed a 2-step approach to haploidentical HSCT that separates the lymphoid and myeloid portions of the graft, allowing fixed T cell dosing to improve consistency in outcome comparisons.

View Article and Find Full Text PDF

There was an increase in the Clostridium difficile infection (CDI) rate in our bone marrow transplantation unit. To evaluate the role of unit-based transmission, C. difficile screening was performed on adult patients admitted for hematopoietic stem cell transplantation (HSCT) over a 2-year period, and C.

View Article and Find Full Text PDF

Background: Spinal fusion procedures are associated with a significant rate of surgical site infection (SSI) (1%-12%). The goal of this study was to identify modifiable risk factors for spinal fusion SSIs at a large tertiary care center.

Methods: A retrospective, case-control (1:3 ratio) analysis of SSIs following posterior spine fusion procedures was performed over a 1-year period.

View Article and Find Full Text PDF

Studies of haploidentical hematopoietic stem cell transplantation (HSCT) have identified threshold doses of T cells below which severe GVHD is usually absent. However, little is known regarding optimal T-cell dosing as it relates to engraftment, immune reconstitution, and relapse. To begin to address this question, we developed a 2-step myeloablative approach to haploidentical HSCT in which 27 patients conditioned with total body irradiation (TBI) were given a fixed dose of donor T cells (HSCT step 1), followed by cyclophosphamide (CY) for T-cell tolerization.

View Article and Find Full Text PDF

Treatment of invasive adenovirus (Ad) disease in hematopoietic stem cell transplant (SCT) recipients with capsid protein hexon-specific donor T cells is under investigation. We propose that cytotoxic T cells (CTLs) targeted to the late protein hexon may be inefficient in vivo because the early Ad protein E3-19K downregulates HLA class I antigens in infected cells. In this study, CD8+ T cells targeted to highly conserved HLA A2-restricted epitopes from the early regulatory protein DNA polymerase (P-977) and late protein hexon (H-892) were compared in peripheral blood (PB) and tonsils of naturally infected adults.

View Article and Find Full Text PDF

Background: Ventriculostomy infections create significant morbidity. To reduce infection rates, a standardized evidence-based catheter insertion protocol was implemented. A prospective observational study analyzed the effects of this protocol alone and with antibiotic-impregnated ventriculostomy catheters.

View Article and Find Full Text PDF
Article Synopsis
  • Recombinant rabies virus (RV)-based vectors have shown promise in generating long-lasting immune responses in animal models, but concerns over safety exist due to the pathogenicity of replication-competent vectors, primarily linked to the RV glycoprotein (RV-G).
  • Researchers have created a live, single-cycle RV by removing the G gene from an HIV-1 Gag-expressing vector, allowing it to be safely propagated while still triggering immune responses.
  • Comparative studies indicate that the single-cycle RV (SPBN-DeltaG-Gag) and the replication-competent RV (BNSP-Gag) induce similar Gag-specific CD8(+) T-cell responses, suggesting that single-cycle RV
View Article and Find Full Text PDF

Although allogeneic hematopoietic progenitor cell transplant (HPCT) is curative therapy for many disorders, it is associated with significant morbidity and mortality, which can be related to graft-versus-host disease (GVHD) and the immunosuppressive measures required for its prevention and/or treatment. Whether the immunosuppression is pharmacologic or secondary to graft manipulation, the graft recipient is left at increased risk of the threatening opportunistic infection. Refractory viral diseases in the immunocompromised host have been treated by infusion of virus-specific lymphotyces and by unmanipulated donor lymphocyte infusion (DLI) therapy.

View Article and Find Full Text PDF

Donor lymphocytes have potential as a treatment for adenovirus (Ad) disease in haematopoietic stem cell transplant (SCT) recipients, but better understanding of Ad-specific T-cell responses is required. Most healthy adults exhibit memory T-cell responses to hexon, a capsid protein synthesized late after infection. However, since the Ad E3-19k downregulates major histocompatibility complex (MHC) class I molecules, cytotoxic T cells (CTLs) targeted to early viral proteins may be more effective in eliminating Ad-infected cells in vivo.

View Article and Find Full Text PDF

Invasive adenovirus (AdV) disease is fatal in >50% of allogeneic hematopoietic stem cell transplant (SCT) recipients. Treatment with cidofovir may improve outcomes based on in vitro susceptibility data and case reports. Six consecutive cases of invasive AdV disease treated with cidofovir were reviewed among 84 allogeneic adult SCT recipients (incidence, 7.

View Article and Find Full Text PDF
Article Synopsis
  • A safer smallpox vaccine may be developed using recombinant subunits from vaccinia virus (VACV) instead of the live virus, focusing on proteins that generate both neutralizing antibodies and T-cell responses.* -
  • Research involving PBMC from VACV vaccinees demonstrated recognition of VACV envelope proteins A27, B5, L1, and A33, indicating both CD4(+) and CD8(+) T-cell responses across different time frames since vaccination.* -
  • Specific T-cell precursors for proteins B5 and A27 were found in recent vaccinees, suggesting that all four envelope proteins are crucial for protective immunity through the induction of both antibody and T-cell responses.*
View Article and Find Full Text PDF
Article Synopsis
  • Adenoviruses are a serious threat to patients who receive stem cell transplants, but there is currently no effective treatment for the infection.
  • Research has found that healthy adults have a significant population of T cells that can specifically target adenovirus hexon protein, which is an important part of the virus.
  • Identifying the hexon protein as the main target for T cells suggests that using donor lymphocyte infusions could be a potential strategy to treat adenovirus infections in patients after stem cell transplantation.
View Article and Find Full Text PDF

Purpose: There is growing interest in developing cellular immune therapies for glioblastoma multiforme, but little is known about tumor-specific T-cell responses. A glioblastoma multiforme-specific T-cell assay was developed using monocyte-derived dendritic cells to present tumor antigens from the established glioblastoma multiforme cell line U118.

Experimental Design: Peripheral blood mononuclear cells (PBMC) and tumor cells were obtained from nine patients with newly diagnosed brain tumors: five glioblastoma multiforme, two oligodendroglioma, one ependymoma, and one astrocytoma.

View Article and Find Full Text PDF

Adenovirus (Ad) infections in immunocompromised hosts have increased in frequency as the number of patients with transplants of bone marrow, liver, kidney, heart and other organs increase in number and survive longer. The numbers of such patients have also increased because of the emergence of the HIV epidemic. Ad infections with the 51 different serotypes recognised to date have few pathognomonic signs and symptoms, and thus require a variety of laboratory-based procedures to confirm infection.

View Article and Find Full Text PDF

The immunogenicity of adenovirus vectors remains a major obstacle to their safe and efficacious use for gene therapy. In order to identify T-cell epitopes directly from adenoviruses, four viral protein sequences were screened for the well-characterized 9-mer HLA-A2 binding motif. Peripheral blood mononuclear cells (PBMC) from healthy adults were tested for responses to 17 selected viral peptides using a short-term interferon-gamma ELISPOT assay.

View Article and Find Full Text PDF